These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8485045)

  • 61. The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b.
    Bergsagel DE; Messner H
    Br J Cancer; 1990 Jun; 61(6):895-8. PubMed ID: 2372493
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia.
    Kloke O; Wandl U; Opalka B; Moritz T; Nagel-Hiemke M; Franz T; Becher R; Hirche H; Seeber S; Niederle N
    Eur J Haematol; 1992 Feb; 48(2):93-8. PubMed ID: 1547881
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival.
    Shepherd P; Suffolk R; Halsey J; Allan N
    Br J Haematol; 1995 Mar; 89(3):546-54. PubMed ID: 7734353
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia.
    Melo JV; Hochhaus A; Yan XH; Goldman JM
    Br J Haematol; 1996 Mar; 92(3):684-6. PubMed ID: 8616036
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Interferon alfa-2b in acute- and chronic-phase chronic myelogenous leukaemia: initial response and long-term results in 54 patients.
    Niederle N; Moritz T; Kloke O; Wandl U; May D; Becher R; Franz T; Opalka B; Schmidt CG
    Eur J Cancer; 1991; 27 Suppl 4():S7-14. PubMed ID: 1799485
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
    Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
    Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Alfa-2a interferon induces molecular remission in post-BMT relapse of chronic myelogenous leukaemia. Report of a case with loss of bcr-abl RNA].
    Casado LF; Steegmann JL; Picó M; Requena MJ; Gómez C; Fernández-Rañada JM
    Sangre (Barc); 1995 Oct; 40(5):417-20. PubMed ID: 8553177
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Recombinant alpha 2B interferon in combination with oral chemotherapy in late chronic phase chronic myeloid leukaemia.
    Giles FJ; Aitchison R; Syndercombe-Court D; Schey S; Newland AC
    Leuk Lymphoma; 1992 May; 7(1-2):99-102. PubMed ID: 1472937
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Response to alpha-interferon in children with Philadelphia chromosome-positive chronic myelocytic leukemia.
    Dow LW; Raimondi SC; Culbert SJ; Ochs J; Kennedy W; Pinkel DP
    Cancer; 1991 Oct; 68(8):1678-84. PubMed ID: 1833044
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cytogenetic response to alpha-interferon is predicted in early chronic phase chronic myeloid leukemia by M-bcr breakpoint location.
    Elliott SL; Taylor KM; Taylor DL; Rodwell RL; Williams BF; Shuttlewood MM; Wright SJ; Eliadis PE; Bunce IH; Frost TJ
    Leukemia; 1995 Jun; 9(6):946-50. PubMed ID: 7596182
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
    Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
    Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies.
    Freund M; von Wussow P; Diedrich H; Eisert R; Link H; Wilke H; Buchholz F; LeBlanc S; Fonatsch C; Deicher H
    Br J Haematol; 1989 Jul; 72(3):350-6. PubMed ID: 2765403
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [The 6M 12M trial--study of the effectivess and tolerance of treatment in chronic myeloid leukaemia with a combination of interferon alfa and cytarabine].
    Tóthová E; Fricová M; Stecová N; Svorcová E; Guman T; Rraffac S; Kafková A; Hlebasková M
    Vnitr Lek; 2000 Jul; 46(7):391-4. PubMed ID: 15635799
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Schaefer UW
    Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment of Ph-positive chronic myeloid leukemia with alpha-interferon (ROFERON-A). The Italian Cooperative Study Group experience. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
    Leuk Lymphoma; 1993; 11 Suppl 1():153-7. PubMed ID: 8251889
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results.
    Guilhot F; Abgrall JF; Harousseau JL; Bauters F; Brice P; Dine G; Tilly H; Ifrah N; Cassasus P; Rochant H
    Leuk Lymphoma; 1993; 11 Suppl 1():181-3. PubMed ID: 8251893
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Chronic myelogenous leukemia: recent developments in prognostic evaluation and chemotherapy. The German CML Study Group.
    Hehlmann R; Heimpel H; Griesshammer M; Kolb HJ; Heinze B; Hossfeld DK; Wickramanayake PD; Essers U; Thiele J; Georgii A
    Leukemia; 1992; 6 Suppl 3():110S-114S. PubMed ID: 1602805
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Alpha interferon: perspectives in the biotherapy of chronic myelogenous leukemia.
    Terebelo HR
    Oncol Nurs Forum; 1991; 18(1 Suppl):5-9. PubMed ID: 1997975
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-alpha therapy.
    Tchirkov A; Giollant M; Tavernier F; Briançon G; Tournilhac O; Kwiatkowski F; Philippe P; Choufi B; Deméocq F; Travade P; Malet P
    Br J Haematol; 1998 Jun; 101(3):552-7. PubMed ID: 9633901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.